Health And Economy News

The latest health and economy stories, summarized by AI

"Ozempic and Weight-Loss Drugs: Boosting the US Economy"

Goldman Sachs strategists predict that the increased use of weight-loss drugs like Ozempic in the US could potentially boost the nation's gross domestic product by an extra 1% over the next decade, equivalent to about $360 billion per year, due to the economic burden of poor health on the labor supply. Drug companies like Novo Nordisk and Eli Lilly are racing to develop obesity drugs, with the market expected to exceed $100 billion by 2030. Goldman projects that 10-70 million Americans could be taking weight-loss drugs by 2028, potentially leading to significant economic spillovers if obesity rates decrease.

1 year ago•Source: Fox Business

"Ozempic Usage to Drive 1% GDP Growth, Warns Goldman Sachs"

health-and-economy

2.825 min•1 year ago

"Ozempic Usage to Drive 1% GDP Growth, Warns Goldman Sachs"

Goldman Sachs predicts that if 60 million Americans take GLP-1 weight loss drugs like Ozempic by 2028, the US GDP could grow by an additional 1%, attributing this to the economic costs of poor health on labor supply and productivity. The drugs have shown promise in improving health outcomes for patients with type 2 diabetes and obesity, potentially leading to significant spillover effects on the broader economy, including increased productivity and GDP growth in excess of current trends.

via Yahoo Finance